Azithromycin has a uniquely long tissue half-life (~70 hours) compared to erythromycin. Which pharmacokinetic property explains this and its single-dose 1g regimen for chlamydial urethritis?

• A Azithromycin is eliminated almost entirely by the kidney, with renal clearance determining its long half-life
• B Azithromycin has very high tissue-to-plasma ratio (Vd > 30 L/kg) due to accumulation in phagocytes, fibroblasts, and intracellular compartments; drug is released slowly from tissues providing sustained concentrations at infection sites ✓
• C Azithromycin undergoes extensive enterohepatic recycling extending its apparent half-life
• D Azithromycin binds irreversibly to 23S rRNA, requiring only a single exposure for persistent antibacterial action

Explanation

Azithromycin has an exceptionally large volume of distribution (31–67 L/kg), reflecting massive intracellular accumulation — particularly in macrophages, neutrophils, and fibroblasts, where concentrations can be 10–100x plasma levels. Azithromycin is actively transported into phagocytes and slowly released at infection sites. This tissue pharmacokinetics, not renal or hepatic half-life, creates sustained intracellular concentrations lasting 5–7 days after a single dose, justifying single 1g dose for uncomplicated chlamydial infection. Its binding to 23S rRNA is reversible (option D is incorrect).

Reference: KD Tripathi, Essentials of Medical Pharmacology, 8th ed.

High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP

Written and medically reviewed by the StethoPrep medical team.